Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Yan YanDepartment of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106.
Xinming WangDepartment of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106.
Hanna JeonDepartment of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106.
Teresa R KeeDepartment of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106.ORCID 0000-0003-4140-6341
Khoi D TranDepartment of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106.
Hyunkyoung LeeDepartment of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106.
Xingyu ZhaoDepartment of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106.
Tian LiuDepartment of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106.ORCID 0000-0002-6437-8892
Simon S WingDepartment of Medicine, Division of Endocrinology and Metabolism, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC H4A 3J1, Canada.ORCID 0000-0001-8394-7563
Jung-A A WooDepartment of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106.ORCID 0000-0002-9194-1361
David E KangDepartment of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106.ORCID 0000-0002-7132-821X
Funding
Decoding the BETA-arrestin2-LMBRD2 cascade in ALPHA-synuclein pathogenesis.RF1NS134638 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI WOO, JUNGA "ALEXA" · 2024 to 2024
$2.1M
SSH1-Nrf2 nexus in tipping the balance between degeneration and protection in tauopathies.R01AG080924 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI David E Kang · 2023 to 2026
$2.0M
Pathological Signatures of CHCHD10 Dysfunction in ADRDsR01NS122350 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI KANG, DAVID E · 2021 to 2025
$2.0M
Deubiquitinase USP11 in tau regulation and age-related tauopathyR01AG067741 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI KANG, DAVID E, WOO, JUNGA "ALEXA" · 2020 to 2024
$2.0M
Deubiquitinase USP19 in TDP-43 pathogenesis.RF1NS122218 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI KANG, DAVID E, WOO, JUNGA "ALEXA" · 2022 to 2022
$1.8M
Deubiquitinase USP19 in TDP-43 pathogenesis.R01NS122218 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI David E Kang, JungA Alexa Woo · 2025 to 2026
$1.2M
BLRD VA I01 BX006539HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R01NS122350HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) RF1NS122218HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) RF1NS134638HHS | NIH | National Institute on Aging (NIA) R01AG067741HHS | NIH | National Institute on Aging (NIA) R01AG080924NIA NIH HHS R01 AG067741NIA NIH HHS R01 AG080924NINDS NIH HHS R01 NS122218NINDS NIH HHS R01 NS122350NINDS NIH HHS RF1 NS122218NINDS NIH HHS RF1 NS134638U.S. Department of Veterans Affairs (VA) I01BX006539
6 · The paper itself
Abstract
Aggregation and deposition of TAR DNA-binding protein 43 (TDP-43) is a salient pathological signature of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration-TDP (FTLD-TDP). TDP-43 proteostasis and aggregation are controlled by several posttranslational modifications, including ubiquitination. While multiple E3 ubiquitin ligases are known to facilitate TDP-43 clearance, little is known about the role of deubiquitinases (DUBs) in controlling TDP-43 proteostasis. Through an unbiased discovery screen of DUBs, here we identify and demonstrate using in vitro and in vivo models, as well as human brain tissue, that ubiquitin-specific peptidase-19 (USP19) acts as a TDP-43-directed DUB that removes K48- and K63-linked ubiquitin conjugates from TDP-43 and preferentially promotes cytoplasmic aggregation of TDP-43 C-terminal fragments (TDP-CTFs) through its catalytic activity. Specifically, the endoplasmic reticulum (ER)-anchored USP19 isoform (USP19-ER) exhibits superior activity in deubiquitinating TDP-CTFs, enhancing its phase separation and aggregation, compared to its cytosolic isoform (USP19-Cyto). Furthermore, as TDP-CTFs are generated at the ER, USP19 acts to couple the aggregation of TDP-CTFs to ER stress (ATF6, ATF4, IRE1, & CHOP). In humans, USP19 protein levels increase in FTLD-TDP brains, which extensively colocalize with cytoplasmic phospho-TDP-43 (pTDP-43) pathology. Importantly, we demonstrate in vivo that genetic reduction of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Ubiquitin-specific peptidase-19 links TDP-43 aggregation to ER stress. · full record | OpenQuestion